Form 4: CytomX CFO Sells Shares for Tax Obligations

CytomX Therapeutics' CFO, Christopher Ogden, sold 19,323 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Christopher Ogden, Chief Financial Officer of CytomX Therapeutics, Inc. (CTMX), reported a transaction involving the company's common stock.
• On March 17, 2026, Mr. Ogden disposed of 19,323 shares of common stock.
• The shares were sold at a price of $6.423 per share.
• The purpose of this sale was solely to satisfy tax or other government withholding obligations in connection with the vesting of restricted stock units (RSUs).
• Following this transaction, Mr. Ogden beneficially owns 296,948 shares of common stock, which includes 173,082 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is a routine tax-related transaction and not indicative of a change in the executive's confidence or the company's operational performance.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that tax-related sales by executives, such as this one, are common and typically do not reflect a change in management's outlook on the company's prospects. These transactions are often pre-scheduled under Rule 10b5-1 plans to manage tax liabilities arising from equity compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related sale, not a discretionary sale indicating a change in sentiment.

Key Dates

Recommendation

The transaction is a routine sale by the CFO to cover tax obligations upon RSU vesting, which is a common and expected event. It does not signal a change in the company's fundamentals or the executive's long-term outlook, thus a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.

Keywords

CytomX Therapeutics, CTMX, Form 4, Insider Trading, Stock Sale, CFO, Restricted Stock Units, RSU Vesting, Tax Withholding